Thrombopoietin directly increases osteoclast formation and differentiation in vitro by activating MAPK, JAK/STAT, and NF-kappaB signaling pathways.
Thrombopoietin directly enhances osteoclast formation and bone resorption via the c-mpl receptor, identifying a novel therapeutic target for bone loss diseases.
Emerging data suggest that megakaryocytes (MKs) play a significant role in skeletal homeostasis. Indeed, osteosclerosis observed in several MK-related disorders may be a result of increased numbers of MKs. In support of this idea, we have previously demonstrated that MKs increase osteoblast (OB) proliferation by a direct cell-cell contact mechanism and that MKs also inhibit osteoclast (OC) formation. As MKs and OCs are derived from the same hematopoietic precursor, in these osteoclastogenesis studies we examined the role of the main MK growth factor, thrombopoietin (TPO) on OC formation and bone resorption. Here we show that TPO directly increases OC formation and differentiation in vitro. Specifically, we demonstrate the TPO receptor (c-mpl or CD110) is expressed on cells of the OC lineage, c-mpl is required for TPO to enhance OC formation in vitro, and TPO activates the mitogen-activated protein kinases, Janus kinase/signal transducer and activator of transcription, and nuclear factor-kappaB signaling pathways, but does not activate the PI3K/AKT pathway. Further, we found TPO enhances OC resorption in CD14+CD110+ human OC progenitors derived from peripheral blood mononuclear cells, and further separating OC progenitors based on CD110 expression enriches for mature OC development. The regulation of OCs by TPO highlights a novel therapeutic target for bone loss diseases and may be important to consider in the numerous hematologic disorders associated with alterations in TPO/c-mpl signaling as well as in patients suffering from bone disorders.
Bethel et al. (Thu,) conducted a other in Bone loss diseases. Thrombopoietin (TPO) was evaluated on Osteoclast formation and differentiation in vitro. Thrombopoietin directly increases osteoclast formation and differentiation in vitro by activating MAPK, JAK/STAT, and NF-kappaB signaling pathways.